Lymphomas with concurrent BCL2 and MYC translocations: The critical factors associated with survival

Blood

Volumn 114, Issue 11, 2009, Pages 2273-2279

  Johnson, Nathalie A ^a   Savage, Kerry J ^a   Ludkovski, Olga ^a   Ben Neriah, Susana ^a   Woods, Ryan ^a   Steidl, Christian ^a   Dyer, Martin J S ^b   Siebert, Reiner ^c   Kuruvilla, John ^a   Klasa, Richard ^a   Connors, Joseph M ^a   Gascoyne, Randy D ^a   Horsman, Douglas E ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; MYC PROTEIN; MYC PROTEIN, HUMAN;

ADULT; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CYTOGENETICS; DEATH; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; FOLLOW UP; GENE TRANSLOCATION; GENETIC ANALYSIS; HIGH RISK PATIENT; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; ONCOGENE MYC; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; AGED; CHROMOSOME 14; CHROMOSOME 18; DISEASE FREE SURVIVAL; FACTUAL DATABASE; GENE EXPRESSION REGULATION; GENETICS; LARGE CELL LYMPHOMA; METABOLISM; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BURKITT LYMPHOMA; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 18; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSLOCATION, GENETIC;

EID: 70349575802     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-03-212191     Document Type: Article

References (47)

1. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985;228:1440-1443. (Pubitemid 15041322)
2. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335:440-442. (Pubitemid 18234863)
3. McDonnell TJ, Deane N, Platt FM, et al. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell. 1989;57:79-88. (Pubitemid 19098870)
4. Weiss LM, Warnke RA, Sklar J, Cleary ML. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med. 1987;317:1185-1189. (Pubitemid 17150330)
5. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A. 1982;79:7824-7827. (Pubitemid 13182471)
6. ar-Rushdi A, Nishikura K, Erikson J, Watt R, Rovera G, Croce CM. Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma. Science. 1983;222:390-393.
7. McClure RF, Remstein ED, Macon WR, et al. Adult B-cell lymphomas with Burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol. 2005;29:1652-1660.
8. Braziel RM, Arber DA, Slovak ML, et al. The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. Blood. 2001;97:3713-3720.
9. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood. 1998;92:3152-3162. (Pubitemid 28492322)
10. Ladanyi M, Offit K, Jhanwar SC, Filippa DA, Chaganti RS. MYC rearrangement and translocations involving band 8q24 in diffuse large cell lymphomas. Blood. 1991;77:1057-1063.
11. Kluin PM, Harris NL, Stein H, et al. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4). Chapter 10. Lyon, France: IARC; 2008:265-266.
12. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008.
13. De Jong D, Voetdijk BM, Beverstock GC, van Ommen GJ, Willemze R, Kluin PM. Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma. N Engl J Med. 1988;318:1373-1378. (Pubitemid 18123879)
14. Gauwerky CE, Haluska FG, Tsujimoto Y, Nowell PC, Croce CM. Evolution of B-cell malignancy: pre-B-cell leukemia resulting from MYC activation in a B-cell neoplasm with a rearranged BCL2 gene. Proc Natl Acad Sci U S A. 1988;85:8548-8552. (Pubitemid 19024999)
15. Kramer MH, Raghoebier S, Beverstock GC, de Jong D, Kluin PM, Kluin-Nelemans JC. De novo acute B-cell leukemia with translocation t(14;18): an entity with a poor prognosis. Leukemia. 1991;5:473-478.
16. Macpherson N, Lesack D, Klasa R, et al. Small noncleaved, non-Burkitt's (Burkitt-like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol. 1999;17:1558-1567.
17. Au WY, Gascoyne RD, Viswanatha DS, et al. Concurrent chromosomal alterations at 3q27, 8q24 and 18q21 in B-cell lymphomas. Br J Haematol. 1999;105:437-440.
18. Le Gouill S, Talmant P, Touzeau C, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica. 2007;92:1335-1342. (Pubitemid 350144150)
19. Christie L, Kernohan N, Levison D, et al. C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: an adverse prognostic indicator? Leuk Lymphoma. 2008;49:470-476. (Pubitemid 351298330)
20. Lin P, Medeiros LJ. High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis. Haematologica. 2007;92:1297-1301. (Pubitemid 350144145)
21. Savage KJ, Ben-neriah S, Connors JM, Horsman D, Gascoyne RD. The prognostic significance of a MYC gene rearrangement in diffuse large B cell lymphoma (DLBCL). Ann Oncol. 2008;19[Suppl 4]:a186.
22. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma: the International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
23. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242. (Pubitemid 34438862)
24. Song KW, Barnett MJ, Gascoyne RD, et al. Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes. Ann Oncol. 2007;18:535-540.
25. Miller TP, Grogan TM, Dahlberg S, et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood. 1994;83:1460-1466. (Pubitemid 24081556)
26. Horsman DE, Connors JM, Pantzar T, Gascoyne RD. Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). Genes Chromosomes Cancer. 2001;30:375-382. (Pubitemid 32216328)
27. Lestou VS, Gascoyne RD, Salski C, Connors JM, Horsman DE. Uncovering novel inter- and intra-chromosomal chromosome 1 aberrations in follicular lymphomas by using an innovative multicolor banding technique. Genes Chromosomes Cancer. 2002;34:201-210. (Pubitemid 34578677)
28. Shaffer LG, Tommerup N. ISCN 2005: An International System for Human Cytogenetics Nomenclature. Basel, Switzerland: Karger; 2005.
29. Nacheva E, Dyer MJ, Fischer P, et al. C-MYC translocations in de novo B-cell lineage acute leukemias with t(14;18)(cell lines Karpas 231 and 353). Blood. 1993;82:231-240. (Pubitemid 23188769)
30. Tanaka S, Louie DC, Kant JA, Reed JC. Frequent incidence of somatic mutations in translocated BCL2 oncogenes of non-Hodgkin's lymphomas. Blood. 1992;79:229-237.
31. Dyer MJ, Lillington DM, Bastard C, et al. Concurrent activation of MYC and BCL2 in B cell non-Hodgkin lymphoma cell lines by translocation of both oncogenes to the same immunoglobulin heavy chain locus. Leukemia. 1996;10:1198-1208. (Pubitemid 26254026)
32. Boerma EG, Siebert R, Kluin PM, Baudis M. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of today's knowledge. Leukemia. 2009;23:225-234.
33. Bertrand P, Bastard C, Maingonnat C, et al. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. Leukemia. 2007;21:515-523. (Pubitemid 46306564)
34. Joos S, Falk MH, Lichter P, et al. Variable breakpoints in Burkitt lymphoma cells with chromosomal t(8;14) translocation separate c-myc and the IgH locus up to several hundred kb. Hum Mol Genet. 1992;1:625-632.
35. Einerson RR, Law ME, Blair HE, et al. Novel FISH probes designed to detect IGK-MYC and IGL-MYC rearrangements in B-cell lineage malignancy identify a new breakpoint cluster region designated BVR2. Leukemia. 2006;20:1790-1799.
36. Johansson B, Mertens F, Mitelman F. Cytogenetic evolution patterns in non-Hodgkin's lymphoma. Blood. 1995;86:3905-3914.
37. Niitsu N, Okamoto M, Miura I, Hirano M. Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma. Cancer Sci. 2009;100:233-237.
38. Wierstra I, Alves J. The c-myc promoter: still MysterY and challenge. Adv Cancer Res. 2008;99:113-333. (Pubitemid 350137254)
39. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419-2430. (Pubitemid 43855045)
40. Hystad ME, Myklebust JH, Bo TH, et al. Characterization of early stages of human B cell development by gene expression profiling. J Immunol. 2007;179:3662-3671.
41. Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: the guardian of B cell identity and function. Nat Immunol. 2007;8:463-470. (Pubitemid 46605911)
42. Masir N, Campbell LJ, Goff LK, et al. BCL2 protein expression in follicular lymphomas with t(14;18) chromosomal translocations. Br J Haematol. 2009;144:716-725.
43. Deng X, Gao F, Flagg T, Anderson J, May WS. Bcl2's flexible loop domain regulates p53 binding and survival. Mol Cell Biol. 2006;26:4421-4434. (Pubitemid 43877564)
44. Ruvolo PP, Deng X, May WS. Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia. 2001;15:515-522.
45. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003;101:4279-4284. (Pubitemid 36857789)
46. Stolz C, Hess G, Hahnel PS, et al. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood. 2008;112:3312-3321.
47. Mason KD, Vandenberg CJ, Scott CL, et al. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc Natl Acad Sci U S A. 2008;105:17961-17966.